Major S. Korea Pharmas Meet To Resolve Issue Of Bribing Doctors
This article was originally published in PharmAsia News
Executive SummaryS. Korea's leading pharmaceutical companies have begun meeting to resolve the issue of companies offering bribes or other favors to physicians and pharmacists to promote their products. The Korea Pharmaceutical Manufacturers Association said 10 major South Korean drug makers discussed the matter. Among those reported to have been represented were Daewoong, Dong-A Pharmaceutical, Hanmi Pharmaceutical and Yuhan. The move comes in the wake of government threats to prosecute several drug firms for offering bribes. (Click here for more
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.